Paper Details

  1. Home
  2. Paper Details

A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.

Author: AlcaláA, AlonsoC, BessesC, BladéJ, García-CondeJ, MaldonadoJ, MoroM J, San MiguelJ, Sanz SanzM A, ZubizarretaA

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 386 patients with multiple myeloma compared MP treatment with a combination of VCMP and VBAP chemotherapy. Combination chemotherapy resulted in a higher response rate, and although no significant difference in survival was found yet, preliminary data suggest a longer survival for patients receiving combination therapy.
Paper Details　
Original Abstract of the Article :
Between January 1985 and December 1988, 386 patients with multiple myeloma were randomized to receive either MP or combination chemotherapy based on alternating cycles of VCMP and VBAP. The major prognostic parameters did not differ significantly between both treatment groups. A significantly higher...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF01737844

データ提供：米国国立医学図書館（NLM）

Multiple Myeloma: A Battleground for New Treatments

Multiple myeloma, a type of blood cancer, can be a challenging desert journey for patients. This research compares two treatment regimens for multiple myeloma: alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone (MP). Imagine a vast desert landscape, where multiple myeloma is a formidable enemy, and treatments are like weapons, each with its strengths and weaknesses.

A Battle of Treatments: VCMP/VBAP vs. MP

The study found that combination chemotherapy (VCMP/VBAP) resulted in a significantly higher proportion of objective responses compared to MP. It's like discovering that one weapon is more effective in achieving a decisive victory against the enemy. While the study did not show a significant difference in overall survival between the two groups, the median survival of MP-treated patients was shorter, suggesting that VCMP/VBAP might offer a potential advantage.

Finding the Right Weapons in the Cancer Desert

This research highlights the importance of continued research and development in the field of multiple myeloma treatment. It's like exploring a desert landscape, searching for the most effective weapons to combat this challenging disease. By understanding the strengths and weaknesses of different treatments, we can better equip ourselves to navigate the desert of multiple myeloma and find a path to recovery.

Dr.Camel's Conclusion

This research delves into the ongoing battle against multiple myeloma, comparing two treatment regimens. It's like analyzing two different weapons in the desert of cancer, seeking the most effective one to defeat the enemy. While further research is needed to fully understand the long-term implications of these treatments, this study offers valuable insights into the fight against multiple myeloma.

Date :
  1. Date Completed 1990-09-06
  2. Date Revised 2019-09-03
Further Info :

Pubmed ID

2198075

DOI: Digital Object Identifier

10.1007/BF01737844

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.